Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
glp 1 incretin The biology of hormones BMI and GLP-1 Weight Size:1 prodotto MCF
BMI and GLP-1 Weight Loss Treatment: What BMI Qualifies? | Doko MD
Who is a good candidate for Ozempic for weight loss
MCF
Size:1 prodotto
CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADER—a landmark CVOT for Victoza ®1 9,340 patients Key inclusion criteria: T2D, A1C ≥7.0% Age ≥50 years and established CVD OR Age ≥60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza ® was 1.78 mg Victoza ® significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
US$ 21.84
US$ 21.16
US$ 24.36
